Revvity, Inc. (NYSE: RVTY), announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status ...

Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune ...

Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support ...

WALTHAM, Mass., March 03, 2025--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a ...

EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood ...

NEW YORK – Revvity said on Monday that its Euroimmun subsidiary has received CE marking under ... The firm said that its Anti-Measles Virus ELISA 2.0 (IgG) is part of an expanding portfolio of ...

Elisa Tonda is the Chief of the Resources and Markets Branch of UNEP's Industry and Economy Division. This Branch works to boost resource-efficient growth and innovation to break the links between ...

Sera were collected 40-45 days after the second dose and anti-SARS-CoV-2 antibody concentrations were measured using the Euroimmun Anti-SARS CoV-2 ELISA IgG kit (Euroimmun, Luebeck, Germany). Briefly, ...

Researchers from the Odense University Hospital in Denmark evaluated the performance of 6 commercially available SARS-CoV-2 antibody detection assays, two of which utilized ELISA (11). Both EUROIMMUN ...